Global hepatitis C prevention & control measures: lessons learnt and opportunities

VHPB Meeting Istanbul Turkey, November 12-13, 2009

Dr Daniel Lavanchy
World Health Organization (WHO)
Hepatitis C global burden

**Hepatitis C - WHO estimate:**

- 2.3 - 4.7 millions new infections
- 300'000 deaths annually
- 130-170 million persons chronically infected
- Not treated, 14 - 45% of patients develop CLD & cirrhosis after ~20 years
New Viral Hepatitis Infections continue to occur:

- unscreened blood transfusions or blood products
- failure to sterilize medical equipment & unsafe injections
- dental and “traditional” medicine?
- injection drug users
- hemodialysis

Prevention Activities
End-stage liver disease

- Cirrhosis > 783,000 deaths / year
- Liver cancer > 619,000 deaths / year

~1 of every 40 death worldwide

But no good breakdown according to aetiology
A comprehensive prevention strategy should include:

- **Primary prevention** of new infections
- **Secondary prevention** of transmission from infected persons to other persons
- **Tertiary prevention** of the pathological consequences of chronic infection in those persistently infected with the virus
Primary prevention of new infections

- Hepatitis C vaccine
  - Investigational E1E2/MF59 vaccine (Novartis)
  - Correlates of protection are complex
  - Human studies in planning stage?
  - Future development?

- Preventing transmission from blood or blood components, organs, tissue and semen through a comprehensive national plan
Secondary prevention of transmission from infected persons to other persons

- Infection control practices
- Safe injection practices
  - Communication for behaviour change > consumer demand for injection safety
  - Reduce number of injections
  - Provision of single-use injection equipment and infection control supplies
  - Sharps waste management
- Special groups
  - Hemodialysis
  - Prisoners
  - IVDU
Tertiary prevention of the pathological consequences

- (peg)-interferon + ribavirin
  - Well established > 40-80% virus elimination
  - Cheaper drugs are partially available

- New antivirals in development

- Treatment is expensive and monitoring is demanding
  - Who should be treated?

- Treatment may not change the public health problem
Strategic approach

- Holistic strategy to improve the prevention, control and management of hepatitis A, B, C & E

- Public health recognition of viral hepatitis as an important issue

- Government lead for a national strategy
  - For awareness raising, screening, diagnosis, referral and treatment
  - Who should lead: The pharmaceutical industry? Doctors? Rock stars? The media?

- Involve advocacy groups, professionals and scientific societies
Success basic requirements

- Clear and consistent messages must be communicated to the general public in order to:
  (governments, NGOs, public health officials, primary care clinicians, advocacy groups)
  - offer the same, complete information
  - raise awareness and understanding
  - overturn misconceptions about Hepatitis B

- set clear, quantifiable targets for
  - reducing incidence and prevalence
  - reducing morbidity & mortality
Epidemiological studies & standardized surveillance data are necessary

- Avoid heterogeneity in availability/quality of data
- Detect outbreaks of HCV infection
- Assess the burden of disease and infection
- Identify risk factors
- Monitoring of chronic liver disease
- Monitor disease trends
- Identify and follow-up infected persons
- Develop, implement, & evaluate prevention programmes
- Evaluation of the effectiveness of activities
  - Vaccination, Screening, Injection safety, infection control, Safe sex, Counseling, Treatment
- Provide guidance for allocation of resources & decision making
Lessons learned

- detection & monitoring of chronic liver disease is unspectacular and therefore difficult to sell
- decision making hampered by heterogeneity in availability/quality of data
- evaluation of the effectiveness of activities is often "forgotten"
- planning about planning revision NoN
Opportunities

- EMRO 2009 & WHO 2010? resolutions
- Use of existing structures – HIV/AIDS, STDs, others
- Use existing tools
- Sell success stories
  - Vaccination, Blood screening, HCC in Taiwan & Italy
- Use influenza surveillance, diagnostic and logistic tools
Conclusions:

- New HCV infections continue to occur
- HCC & cirrhosis will increase
- The public ignores most of HCV related issues
- Implementation of comprehensive national programs for prevention and control still needed in 2009
- Conducting surveillance is demanding but essential for decision making & evaluation of activities
- Further research is necessary to define best practices
- Include patient support groups & “traditional / local” communities with high proportions of immigrants

Epidemic and Pandemic Alert and Response
Thank you

www.who.int

http://www.who.int/topics/hepatitis/en/